Real-world relationship of early endpoints to survival endpoints in patients with resectable non-small-cell lung cancer.
Eric NadlerAnupama VasudevanChuck WentworthNicholas RobertJohn R PenrodJoseph FioreLien VoPublished in: Future oncology (London, England) (2023)
Aim: Pathologic response has been shown to be a promising surrogate for survival in non-small-cell lung cancer (NSCLC). We examined the real-world relationship between these end points in patients with resectable stage IB-IIIA NSCLC receiving neoadjuvant chemotherapy/chemoradiotherapy (CT/CRT). Methods: Electronic health records/medical charts were analyzed. Overall and event-free survival (OS/EFS) were assessed by Kaplan-Meier stratified by pathologic response. Associations between the end points were assessed by Cox analyses. Results: A total of 425 patients were selected for the study; 147 and 278 received CT and CRT, respectively. Pathologic complete response (pCR) was associated with longer OS (adjusted HR = 0.50; 95% CI: 0.29-0.85) and EFS (adjusted HR = 0.44; 95% CI: 0.28-0.68) versus no pCR, and EFS was associated with OS (HR = 0.51, 95% CI: 0.38, 0.69). Conclusion: In patients receiving neoadjuvant CT/CRT, pCR and EFS were associated with improved survival in this real-world dataset.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- free survival
- rectal cancer
- squamous cell carcinoma
- electronic health record
- radiation therapy
- image quality
- dual energy
- computed tomography
- small cell lung cancer
- contrast enhanced
- sentinel lymph node
- end stage renal disease
- cardiac resynchronization therapy
- lymph node
- healthcare
- positron emission tomography
- newly diagnosed
- clinical decision support
- peritoneal dialysis
- heart failure
- real time pcr
- patient reported outcomes
- tyrosine kinase